BlackRock Institutional Trust’s Carisma Therapeutics CARM Stock Holding History

BlackRock Institutional Trust’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$844K	Buy	22,104 +3,151	+17%	+$139K	﹤0.01%	3334
2016 Q3	$1.06M	Buy	18,953 +11,472	+153%	+$854K	﹤0.01%	3272
2016 Q2	$250K	Hold	7,481	–	–	﹤0.01%	3606
2016 Q1	$48K	Hold	7,481	–	–	﹤0.01%	3793
2015 Q4	$450K	Hold	7,481	–	–	﹤0.01%	3525
2015 Q3	$361K	Buy	7,481 +5,818	+350%	+$359K	﹤0.01%	3557
2015 Q2	$94K	Sell	1,663 -351	-17%	-$49.5K	﹤0.01%	3730
2015 Q1	$359K	Buy	2,014 +216	+12%	+$47.2K	﹤0.01%	3560
2014 Q4	$427K	Sell	1,798 -61	-3%	-$13.7K	﹤0.01%	3527
2014 Q3	$414K	Sell	1,859 -239	-11%	-$56.8K	﹤0.01%	3519
2014 Q2	$553K	Buy	2,098 +67	+3%	+$16.6K	﹤0.01%	3544
2014 Q1	$659K	Buy	+2,031	New	+$608K	﹤0.01%	3522

Other funds holding CARM

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Airain Ltd St. Peter Port, Guernsey $2.26B AUM 12.43% 1-Year Est. Return

BlackRock Institutional Trust's CARM Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Carisma Therapeutics (CARM) stake by 17% in Q4 2016, buying an estimated $139K and bringing the position to 22,104 shares worth $844K. The position accounts for ﹤0.01% of the portfolio, ranked #3334.

BlackRock Institutional Trust first reported a position in CARM in Q1 2014 and has held it in 12 quarters since. The position peaked at $1.06M in Q3 2016. 27 funds tracked by Wall St. Rank hold CARM as of Q4 2016.

BlackRock Institutional Trust held 22,104 shares of Carisma Therapeutics worth $844K as of Q4 2016.
BlackRock Institutional Trust bought 3,151 Carisma Therapeutics shares in Q4 2016, an estimated $139K.
Carisma Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3334 holding.
BlackRock Institutional Trust first reported a position in Carisma Therapeutics in Q1 2014 and has held it in 12 quarters since.
BlackRock Institutional Trust's Carisma Therapeutics position peaked at $1.06M in Q3 2016.
27 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.